Cathie Wood’s ARK ETF Published Their Daily Trades for Thursday, April 10th, 2025

input: Cathie Wood’s ARK ETF published their daily trades for Thursday, April 10th, 2025, with a focus on genomic editing and cryptocurrency sectors. The largest investment of the day was in Beam Therapeutics Inc (NASDAQ:BEAM), with ARK’s ARKK ETF acquiring 135,247 shares worth approximately $2.21 million. This purchase underscores ARK’s growing interest in the cutting-edge CRISPR gene editing technology, as Beam Therapeutics is known for its pioneering base editing technology, which allows for precise and targeted genetic modifications.

Cathie Wood’s ARK ETF has been busy today, making several notable trades in the genomic editing and cryptocurrency sectors.

According to reports, ARK’s ARKK ETF engaged in some substantial buying activity. The ETF bought 135,247 shares of Beam Therapeutics (NASDAQ:BEAM) for approximately $2.21 million. This purchase continues a series of investments in Beam this week, showcasing ARK’s growing interest in the cutting-edge CRISPR gene editing technology. Beam Therapeutics is known for its pioneering base editing technology, which allows for precise and targeted genetic modifications.

In the realm of digital currencies, ARK added 11,849 shares of Coinbase Global (NASDAQ:COIN) to its ARKK ETF, amounting to roughly $2.09 million. This move comes amidst a series of recent investments in Coinbase, indicating ARK’s bullish stance on the cryptocurrency exchange platform.

The trade report also highlighted a significant buy of 48,909 shares of Tempus AI (NASDAQ:TEM), a technology company focusing on artificial intelligence and precision medicine, with a total value of approximately $2.14 million. Additionally, ARK invested in 10X Genomics (NASDAQ:TXG), a company specializing in gene sequencing technology, purchasing 191,500 shares valued at around $1.66 million.

On the sell side, ARK’s ARKG ETF parted with 33,500 shares of Repare Therapeutics (NASDAQ:RPTX), a firm engaged in the discovery and development of precision oncology drugs, for a relatively minor sum of $31,155. This continues a trend from the previous week where ARK consistently reduced its holdings in Repare Therapeutics, signaling a strategic shift away from the company.

The daily trade activity reflects ARK’s ongoing strategy to capitalize on disruptive innovation and technology. Investors following ARK’s trades will note the consistent interest in companies like Beam Therapeutics and Coinbase, suggesting a strong belief in the potential of gene editing and cryptocurrency as transformative forces in the near future.